Theralase Provides Bladder Cancer Clinical Study Update

(TSXV:TLT, OTCQB:TLTFF) Theralase® Technologies Inc. provided an update on its Phase II BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) Carcinoma In-Situ (CIS) clinical study (Study II) and its expanding oncology pipeline. Study II enrolled 96 patients, exceeding the statistical analysis plan's calculated population size of 90 patients. Of these, 87 patients have completed the study and 9 remain on study pending secondary endpoint assessment. The patient demographics were: 81% aged ≥ 65 years, 82% male, 83% white, 82% diagnosed with pure CIS, 12% with CIS + T1, 6% with CIS + Ta, 98% BCG-Unresponsive, and 2% BCG-Intolerant. The median number of BCG installations was 15.4. For the primary endpoint (CR at any point in time), 60 out of 93 patients (64.5%) achieved a Complete Response (CR) with a 95% confidence interval of [49.2, 79.9], and 68 out of 93 (73.1%) achieved a Total Response (CR and IR) with a 95% confidence interval of [56.8, 89.5]. For the secondary endpoint (duration of CR at 450 days), 22 out of 54 patients (40.7%) maintained CR (95% CI: [24.6, 56.9]), and 24 out of 54 (44.4%) maintained Total Response (95% CI: [28.6, 60.3]). The median duration of response was 14.9 months (95% CI: 12.1, 17.7). For the tertiary endpoint (safety at 450 days), 87 out of 87 patients (100.0%) were assessed. Treatment Emergent Adverse Events (TEAEs) included hematuria (47.9%), urinary frequency (39.5%), and urinary urgency (32.3%), with median resolution times of 15, 36, and 43 days, respectively. There were 25 (26.9%) Serious Adverse Events documented: 1 Grade I, 3 Grade II, 14 Grade III, 4 Grade IV (all resolved between 1 to 82 days), and 3 Grade V; 92% were not TEAEs. Patients were followed for up to 3 years post-procedure. At 2 years, 11 out of 49 patients (22.4%) maintained CR (95% CI: [10.5, 34.4]); at 3 years, 9 out of 49 (18.4%) maintained CR (95% CI: [7.5, 29.2]). One patient demonstrated a CR for 7 years after a single Theralase® procedure. Study II utilized Ruvidar® (TLD-1433) activated by the TLC-3200 Medical Laser System and was conducted at 11 clinical sites in Canada and the United States. Enrollment into Study II is complete, with full clinical data collected on 87 patients. Theralase® is analyzing and compiling data for submission of a New Drug Submission (NDS) to Health Canada and a New Drug Application (NDA) to the United States FDA, with marketing decisions anticipated in 2027. In 2027, Theralase® will pursue licensing agreements for global marketing and distribution of light-activated Ruvidar®. The company is working with a Good Laboratory Practices (GLP) laboratory to complete GLP toxicology studies for Rutherrin® to determine Maximum Tolerated Dose (MTD) and Human Equivalent Dose (HED) for additional oncological conditions, expected to be completed in 1Q2027. Subject to regulatory approval, Theralase® intends to commence clinical development through Phase 0/I/II adaptive clinical studies for Glioblastoma Multiforme (GBM), Non-Small Cell Lung Cancer (NSCLC), and Muscle Invasive Bladder Cancer (MIBC) in 2027. In 2027, Theralase® also plans to commence GLP toxicology studies for topical Ruvidar® for Herpes Simplex Virus-1 (HSV-1) derived cold sores and, subject to regulatory approval, Phase I/II/III adaptive clinical studies for HSV-1 derived cold sores.

Theralase(R) Releases Q2 2026 Financial Statements

(TSXV: TLT) (OTCQB: TLTFF) Theralase® Technologies Inc., a clinical-stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of various cancers, bacteria and viruses, has released the Company's unaudited interim consolidated financial statements for the six-month period ended June.

Theralase(R) Closes C$3.6 Million Brokered Financing

(TSXV: TLT) (OTCQB: TLTFF) Theralase® Technologies Inc. announced it has closed its previously announced brokered private placement offering, issuing 14,812,500 units at a price of C$0.24 per unit for aggregate gross proceeds of C$3,555,000. Each unit consists of one common share and one common share purchase warrant, with each warrant exercisable at C$0.32 per share until May 20, 2031. The company has received conditional approval to list the warrants underlying the units and anticipates they will commence trading on the TSX Venture Exchange on or about August 27, 2026, subject to final approval. The supplemental indenture authorized a total of 36,115,273 warrants. The company plans to use the proceeds to complete GLP toxicology studies supporting clinical development of Rutherrin® and Ruvidar® for various cancers and herpes simplex virus-induced cold sores, as well as for working capital and general corporate purposes. The agent, Research Capital Corporation, received an aggregate cash commission of C$216,893 and 903,723 non-transferable compensation options, each exercisable to acquire one unit at C$0.24 per unit until May 20, 2031. Roger DuMoulin-White, President, Chief Executive Officer and Chairman of the Board, stated that the company has successfully raised approximately C$11,000,000 in equity and C$1,000,000 in debt under a recurring line of credit over the last 8 months.

Theralase(R) Announces $5 Million Brokered LIFE Offering

(TSXV: TLT) (OTCQB: TLTFF) Theralase® Technologies Inc. has entered into an agreement with Research Capital Corporation to act as the sole agent and sole bookrunner for a brokered private placement offering of units at a price of C$0.24 per Unit, to raise a minimum of C$3,000,000 and up to a maximum of C$5,000,000.16 in aggregate gross proceeds. Each Unit will consist of one common share and one common share purchase warrant, with each warrant exercisable at C$0.32 per share at any time until May 20, 2031. The company will grant the agent an option to increase the size of the offering by up to 15% in Units. The offering is scheduled to close on August 24, 2026, or such other date as agreed upon by the company and the agent, subject to all necessary approvals including TSXV approval. Upon closing, the company shall pay to RCC a cash commission equal to 7% of the aggregate gross proceeds of the offering and broker warrants equal to 7% of the number of Units issued, both subject to reduction to 3.5% for orders on the President's List. The company plans to use the minimum proceeds for completion of GLP toxicology studies, furtherance of GLP toxicology studies, and working capital and general corporate purposes.

Theralase(R) Engages Global One Media to Expand Global Investor Awareness

(TSXV: TLT) (OTCQB: TLTFF) Theralase® Technologies Inc. announced that it has engaged Global One Media Group Pte. Ltd. to provide digital investor marketing and communications services to the Company. Under the agreement, Global One Media will receive a cash fee compensation of US$39,000 for a six-month term commencing August 1, 2026. Global One Media will not receive any securities as compensation, and neither Global One Media nor its principals currently have any direct or indirect interest in the securities of Theralase® or any right or intention to acquire such an interest. The engagement is subject to customary filings and acceptance by the TSX Venture Exchange. Services provided may include social media management and distribution, digital distribution of Company news releases, content creation, executive interviews, podcasts, corporate video production, investor-focused media features, panel discussions and targeted digital advertising. The company projects that Global One Media's digital communication capabilities and international investor network are expected to complement existing investor relations activities and assist the Company in expanding its visibility across North America, Europe and Asia. All distributed materials concerning Theralase® will be based on the Company's publicly disclosed information and will be subject to the Company's prior review and approval.

Theralase(R) Receives Receipt for C$100 Million Base Shelf Prospectus

(TSXV: TLT) (OTCQB: TLTFF) Theralase® Technologies Inc. announced that it has filed and obtained a receipt for a final base shelf prospectus dated June 29, 2026 with the securities regulatory authorities in all provinces and territories of Canada. The Prospectus will allow Theralase® to offer up to C$100 Million of common shares, warrants, subscription receipts, debt securities or any combination thereof over a 25-month period. Roger DuMoulin-White, BSc, P.Eng, Pro.Dir, President and Chief Executive Officer of Theralase®, stated that the approval of the Prospectus provides up to C$100 Million of capital, if and when required, to fund the commercial development of various cancer, virus and bacteria platforms. The Company has no present intention to offer the Securities pursuant to the Prospectus. Any future offering under the Prospectus will be made by way of a Prospectus supplement containing specific terms of the offering and will be filed with the applicable securities regulatory authorities. The Company believes that maintaining access to flexible financing will support its ongoing efforts to create long-term shareholder value, through successful achievement of key clinical, regulatory and commercial milestones. Theralase® is a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses.

Theralase(R) Lists Warrants on the TSXV

(TSXV: TLT) Theralase® Technologies Inc. announced that the TSX Venture Exchange has accepted for listing up to 20,399,050 common share purchase warrants of the Company, bearing the CUSIP: 88337V142, for trading on the TSXV. The Warrants are expected to commence trading on the TSXV at the open of markets on June 9th, 2026, under the trading symbol "TLT.WT". The Warrants were issued pursuant to a brokered private placement that closed on May 20th, 2026, in which the Company issued 19,166,667 units at a price of C$0.24 per Unit and 1,232,383 non-transferrable compensation options to Research Capital Corporation. The Private Placement raised aggregate gross proceeds of C$4,600,000 and included the full exercise of the over-allotment option by the Agent. Each Warrant entitles the holder to purchase one common share at a price of C$0.32 per common share until May 20, 2031. The Warrants are governed by a Warrant Indenture dated May 20, 2026, between the Company and TSX Trust Company of Canada as Warrant Agent. The company projects the anticipated timing of the commencement of trading of the Warrants on the TSXV.

Theralase(R) Releases Q1 2026 Financial Statements

(TSXV: TLT) Theralase® Technologies Inc. released its unaudited interim consolidated financial statements for the three-month period ended March 31st, 2026, reporting total revenue of $132,634, up from $91,190 for the same period in 2025, a 45% increase. Cost of sales for the period was $68,250 (51% of revenue), resulting in a gross margin of $64,382 (49% of revenue), compared to a cost of sales of $77,896 (85% of revenue) and gross margin of $13,294 (15% of revenue) in 2025. Net loss for the quarter was $1,031,785, including $172,118 of net non-cash expenses, compared to a net loss of $1,471,250 and $254,523 of net non-cash expenses in 2025, with the Drug Division representing $803,352 (78%) of this loss. Study II enrolled and treated 92 patients, with interim analysis showing 65.2% (58/89) achieved Complete Response (CR) and 40.4% (21/52) maintained CR at 450 days. There have been 24 Serious Adverse Events (SAEs) reported, with none directly related to the Study Drug or Study Device, and 100% safety at 450 days (82/82). Theralase® intends to submit a New Drug Application to Health Canada and the FDA in 3Q2026, with regulatory decisions anticipated in 1H2027. The company is also preparing to launch a combinational clinical study with Ferring Pharmaceuticals, subject to FDA approval.

Theralase(R) Closes C$4.8 Million Offering

Theralase® Technologies Inc. announced the closing of its previously announced brokered private placement offering of 19,166,667 units at C$0.24 per unit for gross proceeds of C$4,600,000, including the full exercise of the over-allotment option. The company also closed a concurrent non-brokered private placement offering of 673,624 units at the same price for gross proceeds of C$161,669. In total, Theralase® raised gross proceeds of C$4,761,669 under the combined offerings. Each unit consists of one common share and one common share purchase warrant, with each warrant exercisable at C$0.32 until May 20, 2031. The company has applied to the TSX Venture Exchange for the listing of the warrants and warrant shares, subject to approval. Proceeds will be used to further the Phase II BCG-Unresponsive NMIBC CIS clinical study, commence GLP toxicology analysis for Rutherrin®, and for working capital and general corporate purposes. Over the last 5 months, the company has raised approximately C$7,500,000 in equity and C$1,000,000 under a recurring line of credit to strengthen its balance sheet and fund strategic initiatives.

Theralase(R) Announces $4 Million Brokered LIFE Offering

Theralase Technologies Inc. announced it has entered into an agreement with Research Capital Corporation for a brokered private placement offering of units at C$0.24 per unit, aiming to raise a minimum of C$3,000,000 and up to a maximum of C$4,000,000 in aggregate gross proceeds. Each unit consists of one common share and one warrant, with each warrant exercisable at C$0.32 for 60 months after closing. The offering is scheduled to close on May 20th, 2026, subject to necessary approvals, including from the TSX Venture Exchange. Proceeds will be used for clinical studies, toxicology studies, and working capital, with additional initiatives if the maximum is raised. The agent will receive a 7% cash commission and broker warrants equal to 7% of the units issued.

Theralase(R) Releases 2025 Annual Financial Statements and Provides Clinical Study Update

Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company, has released the Company's audited consolidated financial statements for the twelve-month period ended December 31st. The announcement was made from Toronto, Ontario. The company is dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of various cancer, bacteria and viruses. This release provides investors with official financial data for the stated period.